Browsing by Author "Dizdar, Omer"

Filter results by typing the first few letters
Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Chemotherapy and Biological Treatment Options in Breast Cancer Patients with Brain Metastasis: An Update
    (2014) Arslan, Cagatay; Dizdar, Omer; Altundag, Kadri; 25032884
    Introduction: Breast cancer (BC) is the second most common cause of CNS metastasis. Ten to 20% of all, and 38% of human epidermal growth factor-2 (+), metastatic BC patients experience brain metastasis (BM). Prolonged survival with better control of systemic disease and limited penetration of drugs to CNS increased the probability of CNS metastasis as a sanctuary site of relapse. Treatment of CNS disease has become an important component of overall disease control and quality of life. Areas covered: Current standard therapy for BM is whole-brain radiotherapy, surgery, stereotactic body radiation therapy for selected cases, corticosteroids and systemic chemotherapy. Little progress has been made in chemotherapy for the treatment of BM in patients with BC. Nevertheless, new treatment choices have emerged. In this review, we aimed to update current and future treatment options in systemic treatment for BM of BC. Expert opinion: Cornerstone local treatment options for BM of BC are radiotherapy and surgery in selected cases. Efficacy of cytotoxic chemotherapeutics is limited. Among targeted therapies, lapatinib has activity in systemic treatment of BM particularly when used in combination with capecitabine. Novel agents are currently investigated.
  • No Thumbnail Available
    Item
    Correlation of Histopahologic Response and Prognostic Markers with Survival in Locally Advanced Non-Small Cell Lung Cancer Patients Who Have Treated with Neoadjuvant Chemotherapy
    (2015) Kucukoztas, Nadire; Oguz, Arzu; Rahatli, Samed; Dizdar, Omer; Keskin, Gul Sema Yildiran; Ozyilkan, Ozgur; Altundag, Ozden; 0000-0001-8825-4918; 0000-0003-0197-6622; 0000-0001-5588-0306; 0000-0001-6512-6534; 0000-0003-3163-7429; AAD-2817-2021; W-9219-2019; AAM-3226-2021; W-8004-2019; AAJ-3047-2021
  • Thumbnail Image
    Item
    Good Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Alone
    (2014) Rahatli, Samed; Dizdar, Omer; Kucukoztas, Nadire; Oguz, Arzu; Yalcin, Selim; Ozen, Ozlem; Reyhan, Nihan Haberal; Tarhan, Cagla; Yildiz, Ferah; Dursun, Polat; Altundag, Ozden; Ayhan, Ali
    Background: Most patients with endometrial cancer have stage I disease. Adjuvant therapy in stage IB (formerly IC) endometrial cancer is controversial, treatment options including observation or brachytherapy/radiotherapy in grade 1-3 patients with or without chemotherapy. The purpose of this study was to assess the outcomes of our patients with stage IB endometrioid endometrial cancer. Materials and Methods: Sixty two patients with stage IB endometrial cancer and endometrioid histology were retrospectively evaluated. All patients were initially treated surgically by the same surgeon with comprehensive staging, i.e. total abdominal hysterectomy, bilateral salphingooopherectomy, bilateral pelvic and paraaortic lymph node dissection and omentectomy. Adjuvant radiotherapy was discussed with patients and utilized by those who accepted. Adjuvant chemotherapy was not given to any of the patients. Results: Median age was 62 (range, 42-95). Ninety percent of the patients had grade 1-2 disease. Thirteen patients (21%) received intra vaginal brachytherapy (IVBT) and one received whole pelvic radiotherapy (WPRT). Median follow-up time was 46 months (range, 9-77 months). Three patients experienced recurrence (4.8%), two of them died on follow-up and one was still alive at last visit. Two patients with recurrence had FIGO grade 2 tumors and one had a grade 3 tumor. Two patients (3.2%) died without evidence of recurrent disease. Relapse free survival at 5 years was 94.4% and overall survival was 93.1%. Conclusions: Patients with stage IB disease in our study demonstrated relatively low recurrence rates with this stage of endometrial cancer.
  • No Thumbnail Available
    Item
    Is There Any Correlation Between Molecular Subtypes and Blood Groups in Breast Cancer?
    (2014) Kucukoztas, Nadire; Oguz, Arzu; Babacan, Taner; Dizdar, Omer; Rahatli, Samed; Sarici, Saim Furkan; Keskin, Gul Sema Yildiran; Diker, Omer; Akin, Serkan; Altundag, Ozden; Altundag, Kadri; https://orcid.org/0000-0001-5588-0306; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0003-3163-7429; https://orcid.org/0000-0001-7162-4812; https://orcid.org/0000-0002-7542-9229; https://orcid.org/0000-0003-0197-6622; AAM-3226-2021; W-8004-2019; AAJ-3047-2021; GWZ-4666-2022; B-8984-2017; W-9219-2019
  • Thumbnail Image
    Item
    Paraaortic Lymph Node Dissection in Endometrial Cancer; Is It Necessary?
    (2014) Dizdar, Omer; Oguz, Arzu; Kucukoztas, Nadire; Dursun, Polat; Altundag, Ozden; Ayhan, Ali
  • No Thumbnail Available
    Item
    Response Rates of Taxane Rechallenge in Metastatic Breast Cancer Patients, Previously Treated with Adjuvant Taxanes
    (2014) Oguz, Arzu; Babacan, Taner; Dizdar, Omer; Kucukoztas, Nadire; Rahatli, Samed; Keskin, Gul Sema Yildiran; Altundag, Ozden; Altundag, Kadri; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0001-5588-0306; https://orcid.org/0000-0003-3163-7429; https://orcid.org/0000-0003-0197-6622; W-8004-2019; AAM-3226-2021; AAJ-3047-2021; W-9219-2019